jueves, 16 de octubre de 2014
Gilead: Hay "un mundo mejor" pero está por las nubes...HARVONI.
So you thought Gilead's Sovaldi was expensive? Get ready for Harvoni, the company's all-oral hep C combo regimen that won FDA approval on Friday. The cost? $94,500 for a 12-week course of treatment.
The price for the cocktail--which combines NS5A inhibitor ledipasvir and Sovaldi, a drug that recently became the fastest-ever to reach blockbuster status--is already sparking pushback from doctors, payers and consumers alike.
Many were up in arms over Sovaldi's own $84,000 price tag since that drug rolled out early this year. And some have wasted no time letting their new critiques fly.
The National Coalition on Health Care, for one, wrote to Congress to decry the price. With more than 3 million Americans living with hep C, Harvoni "threatens to impose staggering costs on our healthcare system," the letter states. And that's no exaggeration: According to pharmacy benefits manager (PBM) Prime Therapeutics, the coming prescription wave could increase the hep C cost burden on health plans by as much as 40% in 2015--and that's on top of a record-breaking 2014.
"If pharma continues to price based on what the market will bear, I promise you it's not sustainable," Steven Miller, chief medical officer at PBM Express Scripts, told The Wall Street Journal. "We need to start the debate about how we get to a more sustainable model" of drug pricing. (Más)